Biochemical control, an important treatment goal in acromegaly, is defined as age- and sex-normalized IGF-1 and random GH <1 µg/L or normal GH after OGTT <0.4 µg/L. Long-term exposure to elevated levels of IGF-1 and GH can lead to1-3:
- Increased morbidity
- Decreased quality of life
- Reduced life expectancy
1. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148. 2. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517. 3. Schöfl C, Franz H, Grussendorf M, et al; participants of the German Acromegaly Register. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol. 2013;168(1):39-47.
Please see the Summary of Product Characteristics.